



Cite this article: Pintard L, Archambault V. 2018 A unified view of spatio-temporal control of mitotic entry: Polo kinase as the key. *Open Biol.* **8**: 180114.
<http://dx.doi.org/10.1098/rsob.180114>

Received: 28 June 2018
Accepted: 29 July 2018

Subject Area:
cellular biology/molecular biology

Keywords:
cell cycle, mitosis, Polo, Plk1

Authors for correspondence:
Lionel Pintard
e-mail: lionel.pintard@ijm.fr
Vincent Archambault
e-mail: vincent.archambault.1@umontreal.ca

A unified view of spatio-temporal control of mitotic entry: Polo kinase as the key

Lionel Pintard^{1,2} and Vincent Archambault³

¹Cell Cycle and Development Team, Institut Jacques Monod, UMR7592 CNRS—Université Paris Diderot, Sorbonne Paris Cité and ²Equipe labellisée, Ligue contre le Cancer, Paris, France

³Institut de recherche en immunologie et en cancérologie, Université de Montréal, Montréal, Québec, Canada

LP, 0000-0003-0286-4630; VA, 0000-0002-2857-7667

The Polo kinase is an essential regulator of cell division. Its ability to regulate multiple events at distinct subcellular locations and times during mitosis is remarkable. In the last few years, a much clearer mechanistic understanding of the functions and regulation of Polo in cell division has emerged. In this regard, the importance of coupling changes in activity with changes in localization is striking, both for Polo itself and for its upstream regulators. This review brings together several new pieces of the puzzle that are gradually revealing how Polo is regulated, in space and time, to enable its functions in the early stages of mitosis in animal cells. As a result, a unified view of how mitotic entry is spatio-temporally regulated is emerging.

1. Polo is a multi-faceted kinase

Discovered in *Drosophila*, Polo gave its name to the Polo-like kinase (PLK) family, five of which exist in humans (although Plk5 is kinase-inactive) [1,2]. *Drosophila* Polo, mammalian Plk1, *Xenopus* Plx1 and *Caenorhabditis elegans* PLK-1 are clear orthologues at the sequence and functional levels (here, we refer to them collectively as Polo). These Ser/Thr kinases are defined by the presence of an N-terminal kinase domain (KD) and an additional C-terminal domain, termed the Polo-box domain (PBD), which engages in protein interactions [3,4]. In all these systems, Polo promotes centrosome maturation, centromere/kinetochore (KT) function, chromosome condensation, spindle assembly and function and cytokinesis [5,6]. During development, Polo also coordinates cell-cycle progression with cell polarity and cell fate determination [7–9].

To regulate these different functions, Polo must be activated and dynamically recruited to distinct subcellular structures, in space and time [10]. The localization of Polo is mediated by protein interactions with the PBD. This targeting facilitates the phosphorylation of various effectors by the KD of Polo [11]. The PBD is a phospho-peptide binding domain and its interactions are thus often enhanced by prior phosphorylation of the target [12]. This priming phosphorylation is generally mediated by Cdk1 in mitosis; however, in G2 or during mitotic exit, when Cdk1 is less active, Polo tends to phosphorylate its targets to prime its subsequent binding to them (for self-priming) [4]. In addition, the PBD and the KD can engage in a reciprocal inhibitory interaction (figure 1, point 1) [13,14]. The kinase activity, PBD interactions, interdomain inhibition and localization of Polo are all subjected to regulation by post-translational modifications and structural changes [3]. Because these mechanisms work together to control Polo, they need to be understood at the molecular level to fully appreciate the place Polo occupies on the central stage of cell division. Here, we focus on recent progress made in understanding the complex spatio-temporal regulation and functions of Polo in early mitosis.




Figure 1. Spatio-temporal coordination of Polo kinase during mitotic entry in metazoans. 1, Polo kinase (Plk1 in humans) is kept inactive (blue) by an intramolecular interaction between its KD and its PBD, which inhibit each other (red arrows). In this conformation, the nuclear localization signal (NLS, red) of the KD of Polo is buried by the PBD, and amino acid residues of the NLS mediate the inhibitory interaction with the PBD. 2, During G2, Cyclin A–Cdk1 phosphorylates Bora at multiple sites. 3, This event facilitates the activating phosphorylation of Polo by Aurora A (Polo is phosphorylated by Aurora B independently from Bora in *Drosophila* (*Drosophila*)). 4, This phosphorylation of Polo leads to the exposure of the NLS, which becomes accessible to importins that transport active Polo (green) into the nucleoplasm. 5, In human cells, nuclear transport of Plk1 also requires SUMOylation of the PBD by Ubc9, although how this event relates to the phosphorylation, the interdomain interaction or the exposure of the NLS of Plk1 is unknown. 6, In human cells, WAC promotes sustained phosphorylation of Plk1 by Aurora A in the nucleus. 7, Once in the nucleus, active Polo promotes mitotic entry in several ways, as indicated. 8, Coincident with its activation, Polo also re-localizes to nuclear pore complexes (NPCs). 9, This targeting requires the priming phosphorylation of nucleoporins at CDK sites, presumably by Cyclin B–Cdk1, creating PBD docking sites. In *C. elegans*, PLK-1 also contributes to phosphoprimering. 10, At the NPCs, Polo phosphorylates nucleoporins to induce NPC disassembly and nuclear envelope breakdown (NEB).

2. Polo function in mitotic entry revisited: Plk1 is essential for mitotic entry in human cells

The Polo kinase has long been known to promote mitotic entry in various systems. In *Xenopus* extracts, Plx1 (Polo) was isolated as a kinase required to phosphorylate and to activate Cdc25C, the phosphatase required for activation of Cyclin B–Cdk1 [15,16]. As Cyclin B–Cdk1 is the central trigger of mitotic entry, defined by nuclear envelope breakdown (NEB) and chromosome condensation, these results implied that Polo should be required for mitotic entry, acting upstream of Cyclin B–Cdk1 [17]. However, the phenotypes of the *polo* mutants isolated in *Drosophila* suggested that Polo was needed for cells to assemble functional mitotic centrosomes and a bipolar spindle, but mutant neuroblasts did enter mitosis [1]. These phenotypes could have been due to incomplete inactivation of Polo in these tissues, where maternally contributed Polo is gradually depleted in the developing fly. Consistent with a role for Polo in mitotic entry, inactivation of Plk1 (Polo in human cells) by antibody injection in non-transformed human cells caused a majority of cells to arrest in the G2 phase of the cell cycle [18].

However, subsequent inactivation of Plk1 by RNAi or with ATP-competitive chemical inhibitors induced a prometaphase arrest after a delay in G2 or prophase, suggesting that Plk1 was not required for mitotic entry in human cells progressing through normal cell cycles [19–22]. In any case, Plk1 activity was found to be essential for re-entry into mitosis after recovery from DNA damage [23]. Thus, the importance of Polo activity for mitotic entry during an unperturbed cell cycle remained questionable.

Recently, two studies revisited the question and demonstrated that complete inhibition of Plk1 can prevent mitotic entry for hours in a vast majority of hTERT-RPE1, HeLa or RKO cells, even without prior activation of the DNA damage checkpoint [24,25]. Interestingly, mitotic entry was blocked more efficiently in untransformed RPE-1 cells than in the transformed HeLa cells, probably because Plk1 is expressed at higher levels in HeLa cells, as in many cancer cell lines [24]. Overall, the different results obtained in various contexts by different groups over the years can be largely reconciled by the fact that a much lower Polo activity is sufficient to promote mitotic entry than the level of activity required for the cell to build a mitotic spindle and progress through mitosis [26]. Yet, unlike Cdk1 activity which is completely required for mitotic entry from yeast to humans [17],

Polo activity may not be universally required for this transition. For example, in budding yeast, inactivation of Cdc5 (Polo) kinase results in a late anaphase arrest [27,28]. Nevertheless, the recent studies have now firmly established that Plk1 activity is required for mitotic entry in some of the most commonly used human cell lines to study mitosis [24,25].

3. Mechanisms of spatio-temporal regulation of Polo at the G2/M transition

The importance of Polo activity for mitotic entry is reflected by its activation and relocalization during this transition. During mitotic entry, Polo kinase is activated by phosphorylation of an evolutionarily conserved residue located in the activation loop (Thr210 in human Plk1) [29,30]. Phosphorylation at this residue is primarily mediated by Aurora A in vertebrates (figure 1, point 3) [31,32] and possibly also in *C. elegans* [33,34], and by Aurora B in *Drosophila* [35]. Aurora A is enriched at spindle poles, and phosphorylated Plk1 is first detected at centrosomes as human cells enter mitosis [10]. However, concomitant with its activation, Polo is suddenly imported to the nucleus in prophase. This relocalization of Polo has been observed in human cells, *C. elegans* embryos and *Drosophila* cells in culture [36–38]. Moreover, recent work indicates that active Polo kinase needs to enter the nucleus in order to promote mitotic entry. In an elegant set of experiments, Bruinsma *et al.* [39] showed that restricting Plk1 to the cytoplasm only (where it is activated) or to the nucleus only does not allow Plk1 to promote mitotic entry. These observations suggested the existence of a mechanism coupling Polo activation to its nuclear import.

The elucidation of the first crystal structure showing how the KD and PBD of zebrafish Plk1 interact in the inactive state helped solve this mechanism [40]. It revealed how the PBD binds to the KD in a rigid conformation incapable of catalysis, effectively inhibiting it. By examining the structure, Kachaner *et al.* [38] noticed that residues of a known bipartite nuclear localization signal (NLS) in the KD of Plk1 [41] make direct contacts with the PBD and are required for the interdomain inhibitory interaction within Polo. In this closed conformation, the NLS is masked by the PBD, presumably inaccessible to importins. Previous work had shown that phosphorylation of the activation loop in the KD abrogates the interdomain interaction [14], thus potentially exposing the NLS. Working in *Drosophila*, Kachaner *et al.* showed that phosphorylation of Polo is required for the exposure of the NLS and nuclear import of Polo (figure 1, points 3 and 4). As a result, activated Polo is rapidly sent to the nucleus [38]. As this NLS of Polo is widely conserved among eukaryotes [41], this mechanism is probably a general feature of Polo regulation.

Other mechanisms contribute to regulate Polo activation and localization during mitotic entry. In *Drosophila*, the dissociation of the PBD from the KD induced by the phosphorylation of Polo also weakens an interaction of the PBD with Map205 [38]. This protein binds the PBD of Polo and promotes the PBD–KD intramolecular interaction, thereby acting as an allosteric inhibitor of the KD [38,40].

As Map205 is a microtubule-associated protein, phosphorylation of Polo by Aurora B not only relieves Polo from its intramolecular interaction, it also promotes the release of Polo from a sequestration on microtubules, facilitating its relocalization [42,43]. This mechanism also regulates the essential role of *Drosophila* Polo in cytokinesis; however, as no Map205 orthologue has been identified in humans, it remains to be seen if other proteins similarly regulate Plk1 [42].

In human cells, the nuclear localization of Plk1 has recently been shown to depend also on the SUMOylation of the PBD at Lys492 (figure 1, point 5) [44]. This event is catalysed by Ubc9, and is facilitated by the priming phosphorylation of Ubc9 at a CDK site, which enhances its binding to Plk1. It is tempting to speculate that, like phosphorylation of the activation loop, SUMOylation induces a structural change that exposes the NLS in the KD to promote nuclear import of Plk1. The functional relationship between activating phosphorylation of the KD and SUMOylation of the PBD in triggering the nuclear import of Polo remains to be explored. Interestingly, Lys492 is also the site of mono-ubiquitination of Plk1. This event promotes the relocalization of Plk1 from KTJs to the central spindle at the metaphase/anaphase transition [45]. How SUMO and ubiquitin differentially affect the ability of the PBD to interact with different substrates, regulators or the KD of Plk1 has not been investigated.

4. Nuclear Polo promotes mitotic entry

Once in the nucleus, what does Polo do? In *Drosophila*, it was recently shown that Polo needs to enter the nucleus to activate Cdc25 (String) and trigger its relocalization from the nucleus to the cytoplasm, where Cdc25 activates Cdk1 [38]. String is the only form of Cdc25 expressed in *Drosophila* somatic cells. In vertebrates, three genes encode Cdc25 paralogues (Cdc25A, B and C), and they have all been shown to respond to Plk1 activity [46]. Pioneering work in *Xenopus* extracts established that Plx1 phosphorylates and activates Cdc25C, and that this event is required for activation of Cyclin B–Cdk1 [15,16]. Recent work in human cells revealed that Plk1 phosphorylates Cdc25C at multiple sites in its N-terminal region during mitotic entry. Overexpression of a phosphomimetic Cdc25C variant promotes mitotic entry even when Plk1 activity is inhibited, indicating that activation of Cdc25C by Plk1 is sufficient for mitotic entry [24]. It is not clear to what extent Plk1 can also promote mitotic entry by targeting Cdc25A or Cdc25B. Intriguingly, unlike *Drosophila* Cdc25 which is excluded from nucleus following its activation by Polo, human Cdc25C and Cdc25B have been reported to be imported into the nucleus upon phosphorylation by Plk1 [47,48]. That the spatio-temporal regulation of mitotic entry would unfold in completely opposite manners in flies versus humans would be surprising. The spatio-temporal dynamics of the multiple forms of Cdc25 enzymes in humans have not been completely explored, but it is known that Cdc25A and Cdc25B are predominantly nuclear in interphase [49–53]. In *C. elegans*, CDC-25.1, which is essential for embryogenesis, is enriched in the nucleus in early embryos, where it is activated by PLK-1 during the early embryonic divisions [54]. Thus, the activation of Cdc25 in the nucleus

in prophase may be an evolutionarily conserved role of Polo kinase during mitotic entry.

In the nucleus, Polo could also contribute to mitotic entry by additional mechanisms. Wee1 is a Cdk1-inhibitory kinase that resides predominantly in the nucleus [17]. In human cells, Plk1 antagonizes Wee1 by phosphorylating it to induce its ubiquitination and subsequent degradation by the proteasome [55]. Plk1 also phosphorylates cohesins to promote their removal from chromosome arms in prophase [56]. In addition, Plk1 promotes chromosome condensation by phosphorylating condensins [57,58]. Moreover, in multiple species, Polo localizes to the centromere regions starting in prophase, where it could promote the maturation of KTs before NEB to allow their correct attachment to microtubules after NEB [35,37,59]. The importance of bringing Polo activity in the nucleus before NEB for these other functions, and to what extent each event is required for the normal completion of mitosis, has not been dissected in detail (figure 1, point 7).

Polo has been linked to Greatwall (Gwl), a kinase that promotes mitotic entry by antagonizing protein phosphatase 2A in complex with its B55 regulatory subunit (PP2A-B55). As the cell enters mitosis, Gwl becomes active and phosphorylates endosulfine proteins (ENSA and Arpp19 in humans). Once phosphorylated, endosulfines selectively inhibit PP2A-B55, a phosphatase that efficiently targets several mitotic phosphosites [60]. In *Drosophila* and in human cells, Gwl is nuclear in interphase, but in prophase it re-localizes to the cytoplasm where PP2A-B55 is enriched. This localization dynamics is important for Gwl function [61,62]. In *Drosophila*, phosphorylation of Gwl by both Polo and CDK activities promotes Gwl relocalization to the cytoplasm just before NEB [61]. However, this regulation of Gwl was shown to depend on CDK but not Plk1 activity in human cells [62]. Nevertheless, results suggest that Plx1 contributes to activate Gwl during DNA damage checkpoint recovery in *Xenopus* [63]. While these elements point at a collaboration between Polo and Gwl in promoting mitotic entry, genetic interactions in *Drosophila* suggest that Polo can function against Gwl and with PP2A-B55 in regulating mitosis [64,65]. The precise mechanisms linking Polo and the Gwl-PP2A module remain to be elucidated.

In addition to entering the nucleus in prophase, Polo is recruited to the nuclear envelope (NE). In worms and flies, this localization of Polo is striking [37,66]. Work in *C. elegans* revealed that PLK-1 is required for NEB in both meiosis and mitosis [67,68]. Recent studies showed that PLK-1/Plk1 is recruited specifically to the nuclear pore complexes (NPCs) in *C. elegans* and in human cells (figure 1, point 8) [37,69]. In both systems, the PBD of PLK-1/Plk1 interacts with nucleoporins primed for by phosphorylation at CDK sites (figure 1, point 9). In *C. elegans*, PLK-1 also phosphorylates nucleoporins to create additional PBD binding sites [37]. PLK-1 recruitment to the NE does not require its nuclear import because PLK-1 still localizes to the NE upon inactivation of importins. However, the disruption of the reciprocal inhibitory interaction between the KD and the PBD induced by Polo phosphorylation on the activation loop is likely the trigger for the PBD to interact with phosphorylated nucleoporins. In human cells, NPC-localized Plk1 promotes the disintegration of NPCs, at least in part, by phosphorylating Nup98 and Nup53, thereby breaching the permeability barrier of the NE (figure 1, point 10)

[69,70]. Plk1 may target additional NE components to promote NEB.

In summary, it is now clear that Polo relies on built-in mechanisms by which its activation triggers changes in subcellular localization that are required for Polo to coordinate multiple events in space and time as the cell enters mitosis.

5. The upstream trigger: Cyclin A–Cdk1 primes Bora for Polo activation

Now that we understand that Polo kinase activation by phosphorylation also induces its localization to the nucleus, where Polo promotes mitotic entry, it becomes even more crucial to understand the mechanism leading to Polo activation. In human cells, Plk1 phosphorylation on its activation loop requires Bora, which was originally discovered as a cofactor of Aurora A in *Drosophila* in a genetic screen for regulators of asymmetric cell division [71]. Bora accumulates at the G2/M transition in human cells and promotes Plk1 phosphorylation by Aurora A [31,32]. Importantly, this function of Bora in Polo activation is greatly stimulated by its phosphorylation by Cyclin-CDK complexes in both human cells and *C. elegans* [33,34,72,73]. Cyclin-CDK enzymes phosphorylate Bora at multiple sites but phosphorylation of three evolutionarily conserved residues located in the N-terminal, most conserved part of the protein is critical for Bora function in Polo activation, both in *C. elegans* embryos and in human cells [33,72,73]. Thus, Cyclin-CDK enzymes not only orient Plk1 activity by phosphorylating Plk1 substrates to prime their interactions with the PBD, they also directly stimulate Plk1 activation by Aurora A during mitotic entry [34]. In budding yeast, Cdc28/Cdk1 directly activates Cdc5/Polo by phosphorylating its activation loop [74]. Thus, Polo activation by a CDK is conserved from yeast to humans, although Bora and Aurora A act as intermediates in higher eukaryotes.

Which is the physiological Cyclin-CDK complex phosphorylating Bora? Bora contains a conserved cyclin-binding site (Cy) and both Cyclin B-Cdk1 and Cyclin A2-Cdk2 can phosphorylate Bora *in vitro* [33,75]. In human cells, Plk1 is activated before Cyclin B-Cdk1, so even if Cyclin B-Cdk1 can phosphorylate Bora to sustain Plk1 activity during mitosis [76], it is unlikely to be the Cyclin-CDK complex that activates Plk1 in G2. Cyclin A has long been implicated in mitotic entry, but its critical targets in this process have remained unknown [77,78]. Cyclin A associates with Cdk2 in S-phase and then with Cdk1 during G2 before being degraded in prometaphase [79,80]. By an unknown mechanism, Cyclin A partially re-localizes from the nucleus in S-phase to the cytoplasm in G2; moreover, Cyclin A associates with Plk1 and Bora [24,75]. These observations strongly suggested that Cyclin A-Cdk1 phosphorylates Bora in G2 to trigger Plk1 phosphorylation by Aurora A, and in turn mitotic entry (figure 1, point 2).

Recent work in *Xenopus* extracts confirmed this hypothesis and revealed that Cyclin A-Cdk1 phosphorylates Bora to trigger Plk1 activation and mitotic entry [81]. In this system, immunodepletion of either Plk1 or Bora totally prevents mitotic entry [81,82]. Strikingly, mitotic entry can be rescued in Bora-immunodepleted extracts by adding back the N-terminal domain of human or *Xenopus* Bora produced in *Escherichia coli* but not mutated versions of Bora defective in Cyclin binding (mutated on the Cy motif) or lacking the

three evolutionarily conserved CDK-dependent SP phosphorylation sites. However, exogenous Bora failed to rescue mitotic entry in extracts also depleted of Cyclin A. By contrast, Bora thiophosphorylated *in vitro*, and thus resistant to endogenous phosphatases, readily supported mitotic entry in extracts depleted of Bora and Cyclin A. These observations unequivocally demonstrate that Bora is the necessary and sufficient Cyclin A target required for Plx1 activation and mitotic entry. Once Cyclin B–Cdk1 is activated in mitosis, it likely sustains Polo activation by phosphorylating Bora as Cyclin B co-immunoprecipitates with Bora in mitotic cells [33]. Knowledge of the precise mechanism by which Bora (and its phosphorylation by Cyclin A–Cdk1) helps activate Plk1 (Polo) is still lacking and will likely require structural biology approaches.

In addition to Bora, the multi-functional adaptor protein WAC contributes to Plk1 activation by Aurora A and to timely mitotic entry in human cells [83]. In contrast with Bora, which is predominantly cytoplasmic, WAC is a nuclear protein. WAC interacts with the PBD of Plk1 in a phospho-dependent manner. Cyclin–CDK enzymes phosphorylate WAC at multiple Polo-docking sites, which in turn promotes WAC binding to the PBD of Plk1. As WAC also binds Aurora A, it can bring together Aurora A and Plk1. In the future, it will be important to determine whether WAC only acts as a platform that bridges Aurora A and Plk1 or whether it has a more active role in promoting Aurora A activation. Overall, these observations suggest the existence of two complementary mechanisms for Plk1 activation by Aurora A: one cytoplasmic that depends on Bora and the other one nuclear that relies on WAC (figure 1, point 6). Both pathways are primed by mitotic Cyclin–CDK enzymes.

6. Keeping Polo in check: the role of protein phosphatases

During mitosis in human cells, protein phosphatase 1 (PP1) dephosphorylates Thr210 of Plk1 and thereby antagonizes its activity [84]. This event requires Mypt1, a regulatory subunit of PP1, which is phosphorylated at a CDK site to prime its interaction with Plk1. Recent work showed that Cyclin A–Cdk1 phosphorylates Mypt1 in prometaphase to facilitate the downregulation of Plk1 activity at kinetochores [84,85]. Interestingly, Plk1 can also promote its own inactivation by PP1–Mypt1 in the nucleus, before NEB [86]. This occurs by the phosphorylation of the Golgi-associated protein Optineurin by Plk1, which induces the nuclear import of Optineurin in complex with Mypt1. Disrupting this regulation leads to mitotic defects. The precise role of this proposed negative feedback in Plk1 regulation is still unclear. As Plk1 needs to be active in the nucleus to promote mitotic

entry, this inhibition could help deter premature mitotic entry and ensure a timely switch-like activation of Plk1 in the nucleus at the G2/M transition by the mechanisms discussed above. Cyclin A, which promotes S-phase and is primarily nuclear during interphase [87], would be ideally poised to keep Plk1 in check until DNA replication is completed by phosphoprimering Mypt1. In addition to PP1–Mypt1, other phosphatases can contribute to dampen Plk1 activity. For example, PP2A–B55 α dephosphorylates Plx1 in response to the DNA damage response in *Xenopus* extracts [88]. As PP2A–B55 α is mainly in the cytoplasm [89], it may interfere with the initial activation of Plk1 that takes place in that compartment. Further work will be required to fully understand how phosphatases contribute to the spatio-temporal regulation of Polo kinase.

7. Conclusion and perspective

Although still incomplete, the new knowledge of the complex mechanisms enforcing spatio-temporal control of Polo kinase during mitotic entry constitutes a major leap forward in our understanding of cell division at the molecular level. Much work remains to be done to comprehend the regulation and precise functions of Polo kinase in late phases of cell division, including cytokinesis. Understanding the mechanisms regulating Polo opens possibilities to selectively disrupt specific regulatory modes or downstream functions of Polo in order to dissect their importance experimentally. This can be achieved by mutations at specific sites in Polo, inactivation of upstream regulatory enzymes or even the development of small molecule modulators as tool compounds. Several efforts have been deployed to develop PBD inhibitors that could be used to assess the importance of PBD interactions with targets for specific functions of Polo [90]. The development of chemical inhibitors of the NLS of Plk1 is also being attempted [91]. Although these early endeavours have so far failed to produce highly selective, cell-permeable compounds, the future could bring surprising developments. The sustained interest in Plk1 as a target for potential anti-cancer drugs may further enhance this research direction [90].

Data accessibility. This article has no additional data.

Competing interests. We declare we have no competing interests.

Funding. Work on Polo kinase in V.A.'s laboratory is supported by a grant from the Canadian Institutes of Health Research. V.A. holds a fellowship from the Fonds de recherche du Québec—Santé. Work in the laboratory of L.P. is supported by the French National Research Agency under grant no. ANR-17-CE13-0011-01 and by 'La Ligue Contre le Cancer' (Equipe labellisée). L.P.'s team is also supported by the Labex 'Who am I?' Laboratory of Excellence No. ANR-11-LABX-0071, the French Government through its Investments for the Future programme operated by the French National Research Agency (ANR) under grant no ANR-11-IDEX-0005-01.

References

1. Sunkel CE, Glover DM. 1988 polo, a mitotic mutant of *Drosophila* displaying abnormal spindle poles. *J. Cell Sci.* **89**, 25–38.
2. de Carcer G, Manning G, Malumbres M. 2011 From Plk1 to Plk5: functional evolution of polo-like kinases. *Cell Cycle* **10**, 2255–2262. (doi:10.4161/cc.10.14.16494)
3. Archambault V, Lepine G, Kachaner D. 2015 Understanding the Polo Kinase machine. *Oncogene* **34**, 4799–4807. (doi:10.1038/onc.2014.451)
4. Park JE, Soung NK, Johmura Y, Kang YH, Liao C, Lee KH, Park CH, Nicklaus MC, Lee KS. 2010 Polo-box domain: a versatile mediator of polo-like kinase function. *Cell Mol. Life Sci.* **67**, 1957–1970. (doi:10.1007/s00018-010-0279-9)

5. Archambault V, Glover DM. 2009 Polo-like kinases: conservation and divergence in their functions and regulation. *Nat. Rev. Mol. Cell Biol.* **10**, 265–275. (doi:10.1038/nrm2653)
6. Zitouni S, Nabais C, Jana SC, Guerrero A, Bettencourt-Dias M. 2014 Polo-like kinases: structural variations lead to multiple functions. *Nat. Rev. Mol. Cell Biol.* **15**, 433–452. (doi:10.1038/nrm3819)
7. Wang H, Ouyang Y, Somers WG, Chia W, Lu B. 2007 Polo inhibits progenitor self-renewal and regulates Numb asymmetry by phosphorylating Pon. *Nature* **449**, 96–100. (doi:10.1038/nature06056)
8. Dickinson DJ, Schwager F, Pintard L, Gotta M, Goldstein B. 2017 A single-cell biochemistry approach reveals PAR complex dynamics during cell polarization. *Dev. Cell* **42**, 416–434.e11. (doi:10.1016/j.devcel.2017.07.024)
9. Han B, Antkowiak KR, Fan X, Rutigliano M, Ryder SP, Griffin EE. 2018 Polo-like kinase couples cytoplasmic protein gradients in the *C. elegans* zygote. *Curr. Biol.* **28**, 60–69.e8. (doi:10.1016/j.cub.2017.11.048)
10. Bruinsma W, Raaijmakers JA, Medema RH. 2012 Switching Polo-like kinase-1 on and off in time and space. *Trends Biochem. Sci.* **37**, 534–542. (doi:10.1016/j.tibs.2012.09.005)
11. Lowery DM, Lim D, Yaffe MB. 2005 Structure and function of Polo-like kinases. *Oncogene* **24**, 248–259. (doi:10.1038/sj.onc.1208280)
12. Elia AE, Cantley LC, Yaffe MB. 2003 Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. *Science* **299**, 1228–1231. (doi:10.1126/science.1079079)
13. Elia AE *et al.* 2003 The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. *Cell* **115**, 83–95. (doi:10.1016/S0092-8674(03)00725-6)
14. Jang YJ, Lin CY, Ma S, Erikson RL. 2002 Functional studies on the role of the C-terminal domain of mammalian polo-like kinase. *Proc. Natl Acad. Sci. USA* **99**, 1984–1989. (doi:10.1073/pnas.042689299)
15. Kumagai A, Dunphy WG. 1996 Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from *Xenopus* egg extracts. *Science* **273**, 1377–1380. (doi:10.1126/science.273.5280.1377)
16. Qian YW, Erikson E, Taieb FE, Maller JL. 2001 The polo-like kinase Plx1 is required for activation of the phosphatase Cdc25C and cyclin B-Cdc2 in *Xenopus* oocytes. *Mol. Biol. Cell.* **12**, 1791–1799. (doi:10.1091/mbc.12.6.1791)
17. Morgan DO. 2007 *The cell cycle: principles of control*, p. 297. London, UK: New Science Press.
18. Lane HA, Nigg EA. 1996 Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. *J. Cell Biol.* **135**(6 Pt 2), 1701–1713. (doi:10.1083/jcb.135.6.1701)
19. Sumara I, Gimenez-Abian JF, Gerlich D, Hirota T, Kraft C, de la Torre C, Ellenberg J, Peters JM. 2004 Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. *Curr. Biol.* **14**, 1712–1722. (doi:10.1016/j.cub.2004.09.049)
20. Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, Rettig WJ, Kraut N, Peters JM. 2007 The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. *Curr. Biol.* **17**, 304–315. (doi:10.1016/j.cub.2006.12.046)
21. Gilmartin AG *et al.* 2009 Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. *Cancer Res.* **69**, 6969–6977. (doi:10.1158/0008-5472.CAN-09-0945)
22. Burkard ME, Randall CL, Laroche S, Zhang C, Shokat KM, Fisher RP, Jallepalli PV. 2007 Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. *Proc. Natl Acad. Sci. USA* **104**, 4383–4388. (doi:10.1073/pnas.0701140104)
23. van Vugt MA, Bras A, Medema RH. 2004 Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. *Mol. Cell.* **15**, 799–811. (doi:10.1016/j.molcel.2004.07.015)
24. Gheghiani L, Loew D, Lombard B, Mansfeld J, Gavet O. 2017 PLK1 activation in late G2 sets up commitment to mitosis. *Cell Rep.* **19**, 2060–2073. (doi:10.1016/j.celrep.2017.05.031)
25. Aspinall CF, Zheleva D, Tighe A, Taylor SS. 2015 Mitotic entry: non-genetic heterogeneity exposes the requirement for Plk1. *Oncotarget* **6**, 36 472–36 488. (doi:10.18632/oncotarget.5507)
26. Lera RF, Burkard ME. 2012 High mitotic activity of Polo-like kinase 1 is required for chromosome segregation and genomic integrity in human epithelial cells. *J. Biol. Chem.* **287**, 42 812–42 825. (doi:10.1074/jbc.M112.412544)
27. Ratsima H, Ladouceur AM, Pascariu M, Sauve V, Salloum Z, Maddox PS, D'Amours D. 2011 Independent modulation of the kinase and polo-box activities of Cdc5 protein unravels unique roles in the maintenance of genome stability. *Proc. Natl Acad. Sci. USA* **108**, E914–E923. (doi:10.1073/pnas.1106448108)
28. Snead JL *et al.* 2007 A coupled chemical-genetic and bioinformatic approach to Polo-like kinase pathway exploration. *Chem. Biol.* **14**, 1261–1272. (doi:10.1016/j.chembiol.2007.09.011)
29. Qian YW, Erikson E, Maller JL. 1999 Mitotic effects of a constitutively active mutant of the *Xenopus* polo-like kinase Plx1. *Mol. Cell Biol.* **19**, 8625–8632. (doi:10.1128/MCB.19.12.8625)
30. Jang YJ, Ma S, Terada Y, Erikson RL. 2002 Phosphorylation of threonine 210 and the role of serine 137 in the regulation of mammalian polo-like kinase. *J. Biol. Chem.* **277**, 44 115–44 120. (doi:10.1074/jbc.M202172200)
31. Macurek L *et al.* 2008 Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. *Nature* **455**, 119–123. (doi:10.1038/nature07185)
32. Seki A, Coppinger JA, Jang CY, Yates JR, Fang G. 2008 Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. *Science* **320**, 1655–1658. (doi:10.1126/science.1157425)
33. Thomas Y *et al.* 2016 Cdk1 phosphorylates SPAT-1/Bora to promote Plk1 activation in *C. elegans* and human cells. *Cell Rep.* **15**, 510–518. (doi:10.1016/j.celrep.2016.03.049)
34. Tavernier N, Panbianco C, Gotta M, Pintard L. 2015 Cdk1 plays matchmaker for the Polo-like kinase and its activator SPAT-1/Bora. *Cell Cycle* **14**, 2394–2398. (doi:10.1080/15384101.2015.1053673)
35. Carmena M *et al.* 2012 The chromosomal passenger complex activates Polo kinase at centromeres. *PLoS Biol.* **10**, e1001250. (doi:10.1371/journal.pbio.1001250)
36. Lindon C, Pines J. 2004 Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells. *J. Cell Biol.* **164**, 233–241. (doi:10.1083/jcb.200309035)
37. Martino L, Morchoisne-Bolhy S, Cheerambathur DK, Van Hove L, Dumont J, Joly N, Desai A, Doye V, Pintard L. 2017 Channel nucleoporins recruit PLK-1 to nuclear pore complexes to direct nuclear envelope breakdown in *C. elegans*. *Dev. Cell* **43**, 157–171.e7. (doi:10.1016/j.devcel.2017.09.019)
38. Kachaner D, Garrido D, Mehsen H, Normandin K, Lavoie H, Archambault V. 2017 Coupling of Polo kinase activation to nuclear localization by a bifunctional NLS is required during mitotic entry. *Nat. Commun.* **8**, 1701. (doi:10.1038/s41467-017-01876-8)
39. Bruinsma W, Aprelia M, Kool J, Macurek L, Lindqvist A, Medema RH. 2015 Spatial separation of Plk1 phosphorylation and activity. *Front. Oncol.* **5**, 132. (doi:10.3389/fonc.2015.00132)
40. Xu J, Shen C, Wang T, Quan J. 2013 Structural basis for the inhibition of Polo-like kinase 1. *Nat. Struct. Mol. Biol.* **20**, 1047–1053. (doi:10.1038/nsmb.2623)
41. Taniguchi E, Toyoshima-Morimoto F, Nishida E. 2002 Nuclear translocation of plk1 mediated by its bipartite nuclear localization signal. *J. Biol. Chem.* **277**, 48 884–48 888. (doi:10.1074/jbc.M206307200)
42. Kachaner D *et al.* 2014 Interdomain allosteric regulation of Polo kinase by Aurora B and Map205 is required for cytokinesis. *J. Cell Biol.* **207**, 201–211. (doi:10.1083/jcb.201408081)
43. Archambault V, D'Avino PP, Deery MJ, Lilley KS, Glover DM. 2008 Sequestration of Polo kinase to microtubules by phosphoprimer-independent binding to Map205 is relieved by phosphorylation at a CDK site in mitosis. *Genes Dev.* **22**, 2707–2720. (doi:10.1101/gad.486808)
44. Wen D, Wu J, Wang L, Fu Z. 2017 SUMOylation promotes nuclear import and stabilization of Polo-like kinase 1 to support its mitotic function. *Cell Rep.* **21**, 2147–2159. (doi:10.1016/j.celrep.2017.10.085)
45. Beck J *et al.* 2013 Ubiquitylation-dependent localization of PLK1 in mitosis. *Nat. Cell Biol.* **15**, 430–439. (doi:10.1038/ncb2695)
46. Sur S, Agrawal DK. 2016 Phosphatases and kinases regulating CDC25 activity in the cell

- cycle: clinical implications of CDC25 overexpression and potential treatment strategies. *Mol. Cell Biochem.* **416**, 33–46. (doi:10.1007/s11010-016-2693-2)
47. Lobjovs V, Jullien D, Bouche JP, Ducommun B. 2009 The polo-like kinase 1 regulates CDC25B-dependent mitosis entry. *Biochim. Biophys. Acta* **1793**, 462–468. (doi:10.1016/j.bbamcr.2008.12.015)
48. Toyoshima-Morimoto F, Taniguchi E, Nishida E. 2002 Plk1 promotes nuclear translocation of human Cdc25C during prophase. *EMBO Rep.* **3**, 341–348. (doi:10.1093/embo-reports/kvf069)
49. Boutros R, Dozier C, Ducommun B. 2006 The when and wheres of CDC25 phosphatases. *Curr. Opin. Cell Biol.* **18**, 185–191. (doi:10.1016/j.ceb.2006.02.003)
50. Franckhauser C, Mamaeva D, Heron-Milhavet L, Fernandez A, Lamb NJ. 2010 Distinct pools of cdc25C are phosphorylated on specific TP sites and differentially localized in human mitotic cells. *PLoS ONE* **5**, e11798. (doi:10.1371/journal.pone.0011798)
51. Kallstrom H, Lindqvist A, Pospisil V, Lundgren A, Rosenthal CK. 2005 Cdc25A localisation and shuttling: characterisation of sequences mediating nuclear export and import. *Exp. Cell Res.* **303**, 89–100. (doi:10.1016/j.yexcr.2004.09.012)
52. Hoffmann I, Draetta G, Karsenti E. 1994 Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. *EMBO J.* **13**, 4302–4310.
53. Lindqvist A, Kallstrom H, Karlsson Rosenthal C. 2004 Characterisation of Cdc25B localisation and nuclear export during the cell cycle and in response to stress. *J. Cell Sci.* **117**, 4979–4990. (doi:10.1242/jcs.01395)
54. Rivers DM, Moreno S, Abraham M, Ahringer J. 2008 PAR proteins direct asymmetry of the cell cycle regulators Polo-like kinase and Cdc25. *J. Cell Biol.* **180**, 877–885. (doi:10.1083/jcb.200710018)
55. Watanabe N, Arai H, Nishihara Y, Taniguchi M, Hunter T, Osada H. 2004 M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCF _{β -TRCP}. *Proc. Natl Acad. Sci. USA* **101**, 4419–4424. (doi:10.1073/pnas.0307700101)
56. Hauf S, Roitinger E, Koch B, Ditttrich CM, Mechtler K, Peters JM. 2005 Dissociation of cohesin from chromosome arms and loss of arm cohesion during early mitosis depends on phosphorylation of SA2. *PLoS Biol.* **3**, e69. (doi:10.1371/journal.pbio.0030069)
57. Abe S, Nagasaka K, Hirayama Y, Kozuka-Hata H, Oyama M, Aoyagi Y, Obuse C, Hirota T. 2011 The initial phase of chromosome condensation requires Cdk1-mediated phosphorylation of the CAP-D3 subunit of condensin II. *Genes Dev.* **25**, 863–874. (doi:10.1101/gad.2016411)
58. Kagami Y, Ono M, Yoshida K. 2017 Plk1 phosphorylation of CAP-H2 triggers chromosome condensation by condensin II at the early phase of mitosis. *Sci. Rep.* **7**, 5583. (doi:10.1038/s41598-017-05986-7)
59. Kang YH *et al.* 2006 Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBP1 interaction is critical for proper chromosome segregation. *Mol. Cell* **24**, 409–422. (doi:10.1016/j.molcel.2006.10.016)
60. Lorca T, Castro A. 2012 The Greatwall kinase: a new pathway in the control of the cell cycle. *Oncogene* **32**, 79. (doi:10.1038/onc.2012.79)
61. Wang P, Galan JA, Normandin K, Bonneil E, Hickson GR, Roux PP, Thibault P, Archambault V. 2013 Cell cycle regulation of Greatwall kinase nuclear localization facilitates mitotic progression. *J. Cell Biol.* **202**, 277–293. (doi:10.1083/jcb.201211141)
62. Alvarez-Fernandez M *et al.* 2013 Greatwall is essential to prevent mitotic collapse after nuclear envelope breakdown in mammals. *Proc. Natl Acad. Sci. USA* **110**, 17 374–17 379. (doi:10.1073/pnas.1310745110)
63. Peng A, Wang L, Fisher LA. 2011 Greatwall and Polo-like kinase 1 coordinate to promote checkpoint recovery. *J. Biol. Chem.* **286**, 28 996–29 004. (doi:10.1074/jbc.M111.257121)
64. Archambault V, Zhao X, White-Cooper H, Carpenter AT, Glover DM. 2007 Mutations in *Drosophila* Greatwall/Scant reveal its roles in mitosis and meiosis and interdependence with Polo kinase. *PLoS Genet.* **3**, e200. (doi:10.1371/journal.pgen.0030200)
65. Wang P, Pinson X, Archambault V. 2011 PP2A-twins is antagonized by Greatwall and collaborates with Polo for cell cycle progression and centrosome attachment to nuclei in *Drosophila* embryos. *PLoS Genet.* **7**, e1002227. (doi:10.1371/journal.pgen.1002227)
66. Logarinho E, Sunkel CE. 1998 The *Drosophila* POLO kinase localises to multiple compartments of the mitotic apparatus and is required for the phosphorylation of MPM2 reactive epitopes. *J. Cell Sci.* **111**, 2897–2909.
67. Rahman MM, Munzig M, Kaneshiro K, Lee B, Strome S, Muller-Reichert T, Cohen-Fix O. 2015 *Caenorhabditis elegans* polo-like kinase PLK-1 is required for merging parental genomes into a single nucleus. *Mol. Biol. Cell* **26**, 4718–4735. (doi:10.1091/mbc.e15-04-0244)
68. Chase D, Serafinas C, Ashcroft N, Kosinski M, Longo D, Ferris DK, Golden A. 2000 The polo-like kinase PLK-1 is required for nuclear envelope breakdown and the completion of meiosis in *Caenorhabditis elegans*. *Genesis* **26**, 26–41. (doi:10.1002/(SICI)1526-968X(200001)26:1<26::AID-GENE6>3.0.CO;2-0)
69. Linder MI *et al.* 2017 Mitotic disassembly of nuclear pore complexes involves CDK1- and PLK1-mediated phosphorylation of key interconnecting nucleoporins. *Dev. Cell* **43**, 141–156.e7. (doi:10.1016/j.devcel.2017.08.020)
70. de Castro IJ, Gil RS, Ligamari L, Di Giacinto ML, Vagnarelli P. 2017 CDK1 and PLK1 coordinate the disassembly and reassembly of the nuclear envelope in vertebrate mitosis. *Oncotarget* **9**, 7763–7773. (doi:10.18632/oncotarget.23666)
71. Hutterer A, Berdnik D, Wirtz-Peitz F, Zigman M, Schleiffer A, Knoblich JA. 2006 Mitotic activation of the kinase Aurora-A requires its binding partner Bora. *Dev. Cell* **11**, 147–157. (doi:10.1016/j.devcel.2006.06.002)
72. Tavernier N, Noatynska A, Panbianco C, Martino L, Van Hove L, Schwager F, Léger T, Gotta M, Pintard L. 2015 Cdk1 phosphorylates SPAT-1/Bora to trigger PLK-1 activation and drive mitotic entry in *C. elegans* embryos. *J. Cell Biol.* **208**, 661–669. (doi:10.1083/jcb.201408064)
73. Parrilla A, Cirillo L, Thomas Y, Gotta M, Pintard L, Santamaria A. 2016 Mitotic entry: the interplay between Cdk1, Plk1 and Bora. *Cell Cycle* **15**, 3177–3182. (doi:10.1080/15384101.2016.1249544)
74. Mortensen EM, Haas W, Gygi M, Gygi SP, Kellogg DR. 2005 Cdc28-dependent regulation of the Cdc5/ Polo kinase. *Curr. Biol.* **15**, 2033–2037. (doi:10.1016/j.cub.2005.10.046)
75. Cascales HS, Bourdova K, Mullers E, Stoy H, von Morgen P, Macurek L, Lindqvist A. 2017 Cyclin A2 localises in the cytoplasm at the S/G2 transition to activate Plk1. *bioRxiv*. (doi:10.1101/191437)
76. Bruinsma W, Macurek L, Freire R, Lindqvist A, Medema RH. 2014 Bora and Aurora-A continue to activate Plk1 in mitosis. *J. Cell Sci.* **127**, 801–811. (doi:10.1242/jcs.137216)
77. Fung TK, Ma HT, Poon RY. 2007 Specialized roles of the two mitotic cyclins in somatic cells: cyclin A as an activator of M phase-promoting factor. *Mol. Biol. Cell* **18**, 1861–1873. (doi:10.1091/mbc.e06-12-1092)
78. Gong D, Pomerening JR, Myers JW, Gustavsson C, Jones JT, Hahn AT, Meyer T, Ferrell JE. 2007 Cyclin A2 regulates nuclear-envelope breakdown and the nuclear accumulation of cyclin B1. *Curr. Biol.* **17**, 85–91. (doi:10.1016/j.cub.2006.11.066)
79. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. 1992 Cyclin A is required at two points in the human cell cycle. *EMBO J.* **11**, 961–971.
80. den Elzen N, Pines J. 2001 Cyclin A is destroyed in prometaphase and can delay chromosome alignment and anaphase. *J. Cell Biol.* **153**, 121–136. (doi:10.1083/jcb.153.1.121)
81. Vigneron S, Sundermann L, Labbe JC, Pintard L, Radulescu O, Castro A, Lorca T. 2018 Cyclin A-cdk1-dependent phosphorylation of Bora is the triggering factor promoting mitotic entry. *Dev. Cell* **45**, 637–650.e7. (doi:10.1016/j.devcel.2018.05.005)
82. Abrieu A, Brassac T, Galas S, Fisher D, Labbe JC, Doree M. 1998 The Polo-like kinase Plx1 is a component of the MPF amplification loop at the G2/M-phase transition of the cell cycle in *Xenopus* eggs. *J. Cell Sci.* **111**(Pt 12), 1751–1757.
83. Qi F *et al.* 2018 WAC promotes Polo-like kinase 1 activation for timely mitotic entry. *Cell Rep.* **24**, 546–556. (doi:10.1016/j.celrep.2018.06.087)
84. Yamashiro S, Yamakita Y, Totsukawa G, Goto H, Kaibuchi K, Ito M, Hartshorne DJ, Matsumura F. 2008 Myosin phosphatase-targeting subunit 1 regulates mitosis by antagonizing polo-like kinase 1. *Dev. Cell* **14**, 787–797. (doi:10.1016/j.devcel.2008.02.013)

85. Dumitru AMG, Rusin SF, Clark AEM, Kettenbach AN, Compton DA. 2017 Cyclin A/Cdk1 modulates Plk1 activity in prometaphase to regulate kinetochore-microtubule attachment stability. *eLife* **6**, e29303. (doi:10.7554/eLife.29303)
86. Kachaner D, Filipe J, Laplantine E, Bauch A, Bennett KL, Superti-Furga G, Israël A, Weil R. 2012 Plk1-dependent phosphorylation of optineurin provides a negative feedback mechanism for mitotic progression. *Mol. Cell.* **45**, 553–566. (doi:10.1016/j.molcel.2011.12.030)
87. Yam CH, Fung TK, Poon RY. 2002 Cyclin A in cell cycle control and cancer. *Cell Mol. Life Sci.* **59**, 1317–1326. (doi:10.1007/s00018-002-8510-y)
88. Wang L, Guo Q, Fisher LA, Liu D, Peng A. 2014 Regulation of polo-like kinase 1 by DNA damage and PP2A/B55 α . *Cell Cycle* **14**, 157–166. (doi:10.4161/15384101.2014.986392)
89. Santos SD, Wollman R, Meyer T, Ferrell Jr JE. 2012 Spatial positive feedback at the onset of mitosis. *Cell* **149**, 1500–1513. (doi:10.1016/j.cell.2012.05.028)
90. Park JE, Hymel D, Burke Jr TR, Lee KS. 2017 Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents. *F1000Res.* **6**, 1024. (doi:10.12688/f1000research.11398.1)
91. Chen F, Zhuo X, Qin T, Guo X, Zhang C, Lai L. 2017 Designed inhibitor for nuclear localization signal of polo-like kinase 1 induces mitotic arrest. *Chem. Biol. Drug Des.* **89**, 732–740. (doi:10.1111/cbdd.12896)